Strike Pharma uses its proprietary technology for targeted nanoparticle delivery to enable development of in vivo CAR-T therapies.
The Beginning
Strike Pharma was founded in 2020 on the scientific discoveries by Professor Sara Mangsbo and her research team at the Department of Pharmaceutical Sciences, Uppsala University, Sweden, in collaboration with the Drug Discovery and Development Platform at SciLifeLab – an institution for the advancement of molecular biosciences and a national resource of technologies and expertise for life scientists with the aim of bringing researchers together across traditional boundaries and fostering collaborations. A grant allowing the validation of the technology was awarded by UU Innovation, a support organization at Uppsala University that helps researchers to assess the commercial potential of their ideas. The main investors include Eir Ventures, Flerie Invest, Almi Invest, AB Ility and Monesi Förvaltnings AB.